Objectives-The aim of this investigation was to study the glomerular and tubular effects of low doses (15 mg) of methotrexate in patients with rheumatoid arthritis with and without combined treatment with aspirin (2 g single dose). Methods-Renal function was measured by the plasma clearance of EDTA labelled with chromium-51 (51Cr-EDTA) and mercaptoacetyltriglycine labelled with technetium-99 m (9'Tc-MAG-3). Results-Clearance of 5tCr-EDTA was reduced from 98 (6) to 87 (5) ml/min (mean (SEM)) for patients receiving methotrexate only and further reduced to 76 (5) mI/mi for patients receiving methotrexate and aspirin. This effect was reversible as 51Cr-EDTA increased to 85 (6) mI/mm during continued treatment with methotrexate alone. Clearance of 99'Tc-MAG-3 also decreased from 366 (18) to 315 (17) mI/mm in patients receiving methotrexate alone and further to 295 (17) ml/min during treatment with aspirin and methotrexate. Continued treatment with methotrexate alone resulted in a further decrease in the 'mTc-MAG-3 clearance to 253 (17) nl/min. Conclusions-The study shows that treatment with low doses of methotrexate particularly when combined with aspirin affects glomerular and tubular function. These effects may be of clinical importance and renal function should therefore be monitored with more sensitive methods than serum creatinine as this may not reflect these changes.
99'Tc-MAG-3 also decreased from 366 (18) to 315 (17) mI/mm in patients receiving methotrexate alone and further to 295 (17) ml/min during treatment with aspirin and methotrexate. Continued treatment with methotrexate alone resulted in a further decrease in the 'mTc-MAG-3 clearance to 253 (17) nl/min. Conclusions-The study shows that treatment with low doses of methotrexate particularly when combined with aspirin affects glomerular and tubular function. These effects may be of clinical importance and renal function should therefore be monitored with more sensitive methods than serum creatinine as this may not reflect these changes. ( The aim of the present investigation was to study the glomerular and tubular effects of low doses of methotrexate during combined treatment with and without aspirin.
Patients and methods Eleven patients (10 women) with classical or definite RA were included in the study after informed consent. Their mean age was 55 years (range 32-75 years). The mean duration of the disease was two years (range 0 5-6). All patients had active disease with ongoing inflammation with a mean erythrocyte sedimentation rate (Westergren) of 47 mm/h (range 32-71) at the beginning of the study and 29 mm/h (range 12-44) at the end of the study. No patient had a history or clinical signs of renal disease. They all had normal serum creatinine during the study (65-98 ,umol/l) and routine urine analyses were normal. No other concomitant drugs such as antihypertensive drugs, diuretics, or other NSAIDs were taken during the investigation.
Plasma clearance studies were performed before treatment with methotrexate was started and thereafter three times during ongoing treatment with methotrexate (15 mg weekly) by mouth. Clearance studies were performed after a mean of three weeks (range two to eight weeks), five weeks (range three to 12 weeks), and 20 weeks (range 16-24 weeks) of treatment with methotrexate. The methotrexate dose was given in the morning just before the clearance study was started. Aspirin (2 g by mouth) was combined with methotrexate at the third clearance study, i.e. after a mean of five weeks of treatment with methotrexate. On that occasion methotrexate (15 mg) and aspirin (2 g) were given concomitantly by number of NSAIDs, aspirin remains an important drug in the treatment of rheumatic diseases. Combined treatment with aspirin and methotrexate is therefore often prescribed for rheumatic diseases. The major findings of the present study are that long term renal function may be decreased by treatment with methotrexate and that aspirin further impairs kidney function in patients treated with methotrexate.
The glomerular filtration rate was measured as the plasma clearance of 5Cr-EDTA and it showed a significant decrease in all patients treated with methotrexate and during combined treatment with aspirin. As day to day variations in determinations of glomerular filtration rate using this method are only about 5%6 7 the observed decrease in 5Cr-EDTA clearance reflects true changes in the glomerular filtration rate. After stopping treatment with aspirin, glomerular filtration rate increased, which indicates a separate effect of aspirin.
The renal effects of aspirin observed during combined treatment with methotrexate may be caused by several mechanisms. Aspirin may inhibit renal prostaglandin synthesis via the inhibition of cyclo-oxygenase, leading to a reduction in the glomerular filtration rate, particularly when there is also a reduction in renal blood flow. Our finding of a reversible decrease in the glomerular filtration rate during treatment with aspirin agrees with such a hypothesis. Similar decreases of the glomerular filtration rate have been observed during treatment with other NSAIDs only -for example, indomethacin.'
A reduction of renal plasma flow may also be a possible mechanism for the observed decrease in 99mTc-MAG-3 clearance during treatment with methotrexate and aspirin.
Clearance of 99mTc-MAG-3 has been shown to correlate well with renal plasma flow in a variety of circumstances.9-11 As the decrease in 99mTc-MAG-3 clearance was not reversible, however, as was the 5'Cr-EDTA clearance, other mechanisms have to be considered. A direct effect of methotrexate and aspirin on the secretion process of "mTc-MAG-3 may be one possibility. Direct invasive measurement of renal MAG-3 extraction is necessary to validate this hypothesis, which was not carried out in the present study. Of interest is our finding that 99mTc-MAG-3 clearance progressively decreased although aspirin was given only once. A time effect of prolonged methotrexate treatment may be involved. The design of this study cannot answer this question and further experiments are necessary.
Renal function impairment due to treatment with NSAIDs alone may be underestimated as it is often asymptomatic.'2 The clinical importance of renal effects of methotrexate alone or its effect during combined treatment with aspirin as shown here remains to be elucidated.
Side effects on the gastrointestinal and pulmonary systems due to methotrexate treatment are mainly found in elderly patients. Increased hepatic enzyme levels are more often found in patients receiving combined salicylates and methotrexate, and patients with nephritis show side effects more often than patients with normal kidney function. All these observations indicate that methotrexate elimination may deteriorate due to the impairment of renal function.
In summary, this study has shown that treatment with low doses of methotrexate alone or combined with aspirin may decrease the glomerular filtration rate and tubular secretion as assessed by 5Cr-EDTA and 99mTc-MAG-3 clearance. These effects may be of clinical importance and renal function should therefore be monitored with more sensitive methods than serum creatinine as this may not reflect these changes.
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